Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31679945

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2019 Nov 23
First author
Burtness B

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2019 Nov 23;394(10212):1882-1884. doi: 10.1016/S0140-6736(19)32539-5.
    note
    Source null
    related pmid
    31679948
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2020 Feb;17(2):69. doi: 10.1038/s41571-019-0303-4.
    note
    Source null
    related pmid
    31729474
    relationship
    Comment in
  3. citation
    Lancet. 2020 Jan 25;395(10220):272. doi: 10.1016/S0140-6736(20)30116-1.
    note
    Source null
    related pmid
    31982072
    relationship
    Erratum in
  4. citation
    Lancet. 2020 Feb 22;395(10224):564. doi: 10.1016/S0140-6736(20)30254-3.
    note
    Source null
    related pmid
    32087792
    relationship
    Erratum in
  5. citation
    Oral Oncol. 2020 Jun;105:104762. doi: 10.1016/j.oraloncology.2020.104762.
    note
    Source null
    related pmid
    32381470
    relationship
    Comment in
  6. citation
    Lancet. 2020 Aug 8;396(10248):378. doi: 10.1016/S0140-6736(20)30903-X.
    note
    Source null
    related pmid
    32771101
    relationship
    Comment in
  7. citation
    Lancet. 2020 Aug 8;396(10248):378-379. doi: 10.1016/S0140-6736(20)30904-1.
    note
    Source null
    related pmid
    32771102
    relationship
    Comment in
  8. citation
    Lancet. 2020 Aug 8;396(10248):379. doi: 10.1016/S0140-6736(20)30907-7.
    note
    Source null
    related pmid
    32771103
    relationship
    Comment in
  9. citation
    Ann Transl Med. 2020 Aug;8(15):975. doi: 10.21037/atm.2020.03.164.
    note
    Source null
    related pmid
    32953775
    relationship
    Comment in
  10. citation
    Oral Oncol. 2021 Jan;112:104983. doi: 10.1016/j.oraloncology.2020.104983.
    note
    Source null
    related pmid
    33032941
    relationship
    Comment in
  11. citation
    Lancet. 2021 Jun 12;397(10291):2252. doi: 10.1016/S0140-6736(21)01119-3.
    note
    Source null
    related pmid
    34119067
    relationship
    Erratum in

Authors and identifiers

  1. name
    Burtness B
    type
    Author
  2. name
    Harrington KJ
    type
    Author
  3. name
    Greil R
    type
    Author
  4. name
    Soulières D
    type
    Author
  5. name
    Tahara M
    type
    Author
  6. name
    de Castro G Jr
    type
    Author
  7. name
    Psyrri A
    type
    Author
  8. name
    Basté N
    type
    Author
  9. name
    Neupane P
    type
    Author
  10. name
    Bratland Å
    type
    Author
  11. name
    Fuereder T
    type
    Author
  12. name
    Hughes BGM
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Burtness B
    type
    Author
  2. name
    Harrington KJ
    type
    Author
  3. name
    Greil R
    type
    Author
  4. name
    Soulières D
    type
    Author
  5. name
    Tahara M
    type
    Author
  6. name
    de Castro G Jr
    type
    Author
  7. name
    Psyrri A
    type
    Author
  8. name
    Basté N
    type
    Author
  9. name
    Neupane P
    type
    Author
  10. name
    Bratland Å
    type
    Author
  11. name
    Fuereder T
    type
    Author
  12. name
    Hughes BGM
    type
    Author
bibliography ids
  1. nci-bib-138e9eefeb4daa75e0ec02a0
book metadata
content sha256
1d64fbb538f00b4528e6cb696256389553d1604a86d080fe5731f2219af8890d
document type
citation
dois
  1. 10.1016/S0140-6736(19)32591-7
electronic publication date
display
2019 Nov 1
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31679945
immutable id
pubmed:31679945@1d64fbb538f00b4528e6cb696256389553d1604a86d080fe5731f2219af8890d
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10212
name
Lancet (London, England)
nlm unique id
2985213R
pages
1915-1928
volume
394
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2019 Nov 23;394(10212):1882-1884. doi: 10.1016/S0140-6736(19)32539-5.
    note
    Source null
    related pmid
    31679948
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2020 Feb;17(2):69. doi: 10.1038/s41571-019-0303-4.
    note
    Source null
    related pmid
    31729474
    relationship
    Comment in
  3. citation
    Lancet. 2020 Jan 25;395(10220):272. doi: 10.1016/S0140-6736(20)30116-1.
    note
    Source null
    related pmid
    31982072
    relationship
    Erratum in
  4. citation
    Lancet. 2020 Feb 22;395(10224):564. doi: 10.1016/S0140-6736(20)30254-3.
    note
    Source null
    related pmid
    32087792
    relationship
    Erratum in
  5. citation
    Oral Oncol. 2020 Jun;105:104762. doi: 10.1016/j.oraloncology.2020.104762.
    note
    Source null
    related pmid
    32381470
    relationship
    Comment in
  6. citation
    Lancet. 2020 Aug 8;396(10248):378. doi: 10.1016/S0140-6736(20)30903-X.
    note
    Source null
    related pmid
    32771101
    relationship
    Comment in
  7. citation
    Lancet. 2020 Aug 8;396(10248):378-379. doi: 10.1016/S0140-6736(20)30904-1.
    note
    Source null
    related pmid
    32771102
    relationship
    Comment in
  8. citation
    Lancet. 2020 Aug 8;396(10248):379. doi: 10.1016/S0140-6736(20)30907-7.
    note
    Source null
    related pmid
    32771103
    relationship
    Comment in
  9. citation
    Ann Transl Med. 2020 Aug;8(15):975. doi: 10.21037/atm.2020.03.164.
    note
    Source null
    related pmid
    32953775
    relationship
    Comment in
  10. citation
    Oral Oncol. 2021 Jan;112:104983. doi: 10.1016/j.oraloncology.2020.104983.
    note
    Source null
    related pmid
    33032941
    relationship
    Comment in
  11. citation
    Lancet. 2021 Jun 12;397(10291):2252. doi: 10.1016/S0140-6736(21)01119-3.
    note
    Source null
    related pmid
    34119067
    relationship
    Erratum in
outcomes validated
false
pmid
31679945
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
d049e79fb557a6f32e6dc10596253ba63ecd71154446022b9b59342c1b219b69
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2019 Nov 23
precision
day
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31679945/
title
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Preserved source evidence · Not medical advice